期刊文献+

中剂量环磷酰胺为主的联合化疗加同一剂量G-CSF动员恶性血液病患者自体外周血干细胞 被引量:1

原文传递
导出
摘要 目的:观察中剂量环磷酰胺(CTX)为主的联合化疗加G-CSF对恶性血液病患者自体外周血造血干细胞(APBSC)的动员效果。方法:31例患者接受中剂量CTX2.2g/m^2(1.8g/m^2~3.0g/m^2)联合VPl6(600mg~800mg,或Ara-C(1.0g/m^2~2.0g/m^2)化疗,WBC降至最低值后开始皮下注射G-CSF300ug/d直至采集结束。WBC≥(3.0~5.0)×10^9/L时开始采集,当单个核细胞(MNC)累计≥3.8×10^8/kg或CD34^+细胞≥2.0×10^6/kg时停止采集。结果:采集次数为(2.9±1.0)次,G-CSF持续应用时间为(7.4±2.0)d,采集到的MNC细胞数为(5.53±2.54)×10^8/kg,CD34^+细胞数为(9.46±7.24)×10^6/kg,CFU-GM(46.02±70.58)×10^4/kg。全部移植患者造血功能均获满意重建。结论:中剂量CTX为主的联合化疗加同一剂量G-CSF对血液病患者的APBSC动员是安全、有效的。
出处 《白血病.淋巴瘤》 CAS 2004年第4期226-228,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献7

  • 1Watanabe T, dave B, Heimann DG, et al.Cell adhesion molecule expression on CD+34cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation [J].EXP Hematol, 1998,26(1): 10-18.
  • 2Dazzic C, Cariello A, Rosti G, et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G- CSF and G- CSF alone in patients with non-Hodgkins lymphoma[J]. Leuk Lymphoma, 2000, 39(3-4): 301-310.
  • 3Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 g/m2 or 7 g/m2) and granulccyte colony-stimulating factor in patients with multiple myeloma [J]. Bone Marrow Transplant, 1996,
  • 4Schwartzerg L S, Weaver C H, Birch R, et al. A randomized trail of two doses of cyclophosphamide with etoposide and GCSF for mobilization of peripheral blood stem cells in 318 patients with stage Ⅱ-Ⅲbreast cancer [J]. J Hematother, 1998, 7:141-150.
  • 5Bellucci R, Propris MSD, Buccisano F, et al. Modulation of VLA-4 and L-select in expression on normal CD +34 cells during mobilization with G-CSF [J]. Bone Marrow Transplant, 1999,23 (1):1-8.
  • 6Stadtmauer E A, Schneider C J, Silberstein LE, et al. Peripheral blood progenitor cell generation and harvesting [J]. Semin Oncol 1995,22:291-300.
  • 7Desikan K R, Jagannath S, Siegel D, et al.Collection of more hematopoietic progenitor cell with large volume leukapheresis in patients with multiple myeloma [J]. Leuk Lymphoma, 1998, 28(5-6):501-508.

同被引文献6

  • 1Gahrton G,Tura S,Ljungman P,et al.Prognostic factors in allogenetic bone marrow transplantation for multiple myeloma.J Clin Oncol,1995,13:1312-1322.
  • 2Bensinger W I,Rowley S D,Demirer T,et al.High dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma.J Clin Oncol,1996,14:1447-1456.
  • 3Harousseau J L,Attal M.High-dose therapy in multiple myeloma.Hematol J,2003,4:163-170.
  • 4Bladé J,Samson D,Reece D,et al.Criteria for evahuating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant.Br J Haematol,1998,102:1115-1123.
  • 5Attal M,Harousseau J L,Facon T,et al.Single versus double autologous stem cell transplantation for multiple myeloma.N Engl J Med,2003,349:2495-2502.
  • 6杨玉花,王良绪,赵昕.自体外周血造血干细胞移植治疗多发性骨髓瘤12例临床疗效观察[J].中华血液学杂志,1998,19(11):590-591. 被引量:4

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部